Pro-PEG3-BA
Pro-PEG3-BA is an EML4-ALK/EGFR PROTAC degrader, degrading EML4 ALK and EGFR mutant (L858R/T790M) with DC50 values of 0.42 and 13.50 μM, respectively. Pro-PEG3-BA hinders proliferation and induces cell cycle arrest and apoptosis of NSCLC cells in vitro. Pro-PEG3-BA shows safety profile and decreases EML4-ALK protein via rewiring the ubiquitin- proteasome system in vivo. Pro-PEG3-BA can be used for non-small cell lung cancer research.
(Pink: EGFR and EML4-ALK ligand (HY-150908); Blue: Ligands for E3 Ligase ligand (HY-Y0252); Black: linker (HY-W040165)).
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3057939-64-4
- Fòrmula: C37H52ClN8O7P
- Peso molecular:787.28
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas PROTACs
MoreVer todos los productos específicos de isoformas EGFR
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H1975 | IC50 |
8.8 μM
Compound: Pro-PEG3-BA
|
Inhibition of cell viability in human NCI-H1975 cells incubated for 48 to 72 hrs by CCK8 assay
Inhibition of cell viability in human NCI-H1975 cells incubated for 48 to 72 hrs by CCK8 assay
|
[PMID: 39114932] |
Pro-PEG3-BA (0-50 min) binds to purified ALK with a Kd of 387 nM in vitro [2]. Pro-PEG3-BA binds GID4 protein with Kd value of 6.05 μM in HEK293T cells[3].
Pro-PEG3-BA (0-20 μM, 48 h) specifically degradest EML4 ALK fusion in H3122 (EML4-ALK), with no effect on wild type or mutant ALK[3].
Pro-PEG3-BA (48-72 h) inhibits H3122 cells (48 h) prolifetion with an IC50 value of 0.16 μM, inhibits H1975 cells (EGFR-L858R/T790M) (72 h) prolifetion with an IC50 value of 8.80 μM[3].
Pro-PEG3-BA (48-72 h) inhibits cell growth with an IC50 value of 0.16 μM for H3122 (EML4-ALK) cells (48 h), and 8.8 μM for H1975 (EGFR-L858R/T790M) (72 h) cells, with little toxicity to normal cells (HEK293T cells)[3].
Pro-PEG3-BA (10 μM, 24 h) dramatically downregulates ALK protein abundance alongside CD2AP, MRPS23, RNF2, RAB18 and TRMT10C, demonstrating high selectivity in targeting ALK for degradation; concurrently, it upregulates POLR2F, WASHC2C, NCOR2, ZNF622, ALDH6A1, PRRC1, GPD1L, EXOC7, WACPAF1 in H1975 (EGFR L858R/T790M) cells[3].
Pro-PEG3-BA (10-20 μM, 0-24 h) induces the apparent reduction of EML4-ALK or EGFR mutant proteins in a time-dependent manner in H3122 (EML4-ALK) cells (10 μM) and H1975 (EGFR-L858R/T790M) cells (20 μM)[3].
Pro-PEG3-BA (0.5-20 μM, 6 or 12 h) reduces the levels of EML4-ALK and EGFR mutants in a proteasome-dependent manner in H3122 (EML4-ALK) and H1975 (EGFR-L858R/T790M) cells[3].
Pro-PEG3-BA (5-10 μM, 48-72 h) induces cell cycle arrest and apoptosis in H1975 (EGFR-L858R/T790M) cells and H3122 (EML4-ALK) cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:H3122 cells (EML4-ALK), SK-N-BE(2) (express wild type ALK, and SH-SY5Y) and SH-SY5Y (harbors the ALK-F1174L)
-
Concentration:0, 0.01, 0.1, 1, 10 and 20 μM
-
Incubation Time:48 h
-
Result:Led to a noticeable downregulation of the EML4-ALK protein in H3122 (EML4-ALK) cells.
Did not affect the protein levels of either wild-type or mutant ALK.
-
Cell Line:H3122 cells (EML4-ALK) and H1975 (EGFR L858R/T790M) cells
-
Concentration:0.5 or 20 μM
-
Incubation Time:6 h and 12 h
-
Result:Mediated the degradation of EML4-ALK or EGFR mutant, which was blocked by the proteasome inhibitor MG132 (HY-13259) (10 μM) instead of lysosome inhibitor Chloroquine (HY-17589A) (25 μM).
-
Cell Line:H3122 (10 μM) and H1975 (20 μM )
-
Concentration:H3122 (10 μM) and H1975 (20 μM)
-
Incubation Time:0, 12, 24, 36, 48 and 72 h
-
Result:Induced the apparent reduction of EML4-ALK or EGFR mutant proteins, with effects observed around 45 min and 12 h.
-
Cell Line:H3122 cells (EML4-ALK) and H1975 (EGFR L858R/T790M) cells
-
Concentration:5 or 10 μM
-
Incubation Time:48 (for H3122 cells) or 72 h (for H1975 cells)
-
Result:Induced an accumulation of cells in the G1 phase and concurrently causing a decrease in the number of cells in the S or G2 phase.
Significantly increased the proportion of both early and late apoptotic cells in a concentration-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:H3122 cells induced-female nude mice[3]
-
Dosage:10 mg/kg
-
Administration:i.p., every other day for a total of 8 doses
-
Result:Did not cause significant variations in the mice body weight.
Decreased EML4-ALK protein levels in tumors.
Chemical Information
-
No. CAS 3057939-64-4
-
Peso molecular 787.28
-
Fòrmula C37H52ClN8O7P
-
SMILES
COC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)P(C)(C)=O)=N2)C=CC(N4CCN(CC4)C(CCOCCOCCOCCNC([C@@H]5CCCN5)=O)=O)=C1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Chen X, et al. Mighty mini-PROTACs: an emerging class of degraders. Eur J Med Chem. 2026 Jan 5;301:118202. [Content Brief]
[2]. Zhang J, et al. Linker-free PROTACs efficiently induce the degradation of oncoproteins. Nat Commun. 2025 May 23;16(1):4794. [Content Brief]
[3]. Zhang J, et al. Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC). J Med Chem. 2024 Aug 22;67(16):13666-13680. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)